Immuno-Oncology | Specialty

Less Common Side Effects With Immunotherapy in Melanoma

February 8th 2017

Immunotherapy in Melanoma: Recognizing an Endocrinopathy

February 8th 2017

Melanoma: Testing for Immunotherapy-Related Hepatotoxicity

February 8th 2017

Immunotherapy-Related Pulmonary Toxicities in Melanoma

February 8th 2017

Managing Gastrointestinal Toxicities in Melanoma

February 8th 2017

Melanoma: Management of Dermatologic Toxicities

February 8th 2017

Overall Toxicities With Immunotherapy in Melanoma

February 8th 2017

Monotherapy Versus Combination Therapy Approaches in Melanoma

February 8th 2017

Melanoma: Speed and Durability of Therapeutic Response

February 8th 2017

BRAF-Mutant Melanoma: Frontline Decisions

February 8th 2017

Immunotherapy in BRAF Wild-Type Melanoma

February 8th 2017

Initial Treatment Approach in Advanced Melanoma: Factors to Consider

February 8th 2017

Explaining Therapeutic Options to Patients With Advanced Melanoma

February 8th 2017

Multidisciplinary Care for Advanced Melanoma at Georgetown University

February 8th 2017

Team Approach to Advanced Melanoma Treatment at MSKCC

February 8th 2017

Complex Scenarios in Advanced Melanoma: Examining Three Patient Cases

February 8th 2017

Despite significant developments on the advanced melanoma treatment front, “many clinical scenarios remain where there is no clear-cut course of action," said Robert H.I. Andtbacka, MD, CM, during a recent OncLive Peer Exchange®.

Nab-Paclitaxel Paired With Anti-PD-L1 Immunotherapies in TNBC Studies

February 8th 2017

Combination regimens that pair nab-paclitaxel with PD-L1 checkpoint blockade immunotherapy agents are emerging as a robust area of investigation in triple-negative breast cancer, bolstered by clinical trial results that establish the chemotherapeutic agent as an effective partner for other therapies.

Dr. Socinski on Recent Setbacks in Immunotherapy Combinations in NSCLC

February 7th 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses recent setbacks in immunotherapy combinations in non–small cell lung cancer (NSCLC).

Atezolizumab/Bevacizumab Combo Attains 90% DCR in MSI-High mCRC

February 7th 2017

Patients with microsatellite-high metastatic colorectal cancer responded to an immunotherapy-containing regimen, according to results of a preliminary clinical evaluation presented at the 2017 Gastrointestinal Cancers Symposium.

Dr. Sklar on Challenges With Clinical Trials in Bladder Cancer

February 7th 2017

Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses some of the challenges that come with conducting clinical trials in the treatment of patients with bladder cancer.